阿加曲班联合尤瑞克林治疗脑梗死患者的临床效果  

Clinical Effect of Agalotreban Combined with Eurekline in the Treatment of Cerebral Infarction Patients

作　　者：洪冰聪[1] 王杰华[1] 杨小霞[1] HONG Bingcong;WANG Jiehua;YANG Xiaoxia(Quanzhou First Hospital,Quanzhou 362000,China)

机构地区：[1]福建省泉州市第一医院,福建泉州362000

出　　处：《中国医学创新》2021年第23期139-142,共4页Medical Innovation of China

摘　　要：目的:分析阿加曲班联合尤瑞克林治疗脑梗死患者的临床效果。方法:选取本院2018年10月-2020年9月收治的脑梗死患者102例,按照入院治疗的先后顺序分为对照组和试验组,各51例。对照组接受尤瑞克林治疗,试验组采用阿加曲班联合尤瑞克林治疗。对比两组患者治疗前后的神经缺损情况、血液流变学情况、生存质量和血清C反应蛋白(CRP)、白细胞介素-2(IL-2)水平,同时对比两组患者治疗后的功能恢复情况和不良反应发生情况。结果:治疗后,试验组患者mRS评分、NIHSS评分均明显优于对照组,生存质量评分高于对照组,CRP、IL-2水平均明显低于对照组,血液流变学改善均明显优于对照组,差异均有统计学意义(P<0.05);两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论:应用阿加曲班联合尤瑞克林治疗脑梗死,能够有效促进患者功能恢复,改善神经缺损情况,降低炎症因子水平,从而达到改善疾病预后、提高患者生活质量的目的,且不增加不良反应发生率,值得临床推广使用。Objective:To analyze the clinical effect of Agatroban combined with Eurekline in the treatment of cerebral infarction patients.Method:A total of 102 patients with cerebral infarction admitted to our hospital from October 2018 to September 2020 were selected,they were divided into control group and experimental group according to the order of hospitalization,with 51 cases in each group.The control group received Eurekline treatment,and the experimental group received Agatroban combined with Eurekline treatment.Neurological defects,hemorheology,quality of life,serum C-reactive protein (CRP) and interleukin-2 (IL-2) levels were compared between the two groups before and after treatment,and functional recovery and the occurrence of adverse reactions were compared between the two groups after treatment.Result:After treatment,mRS score and NIHSS score of experimental group were significantly better than those of the control group,quality of life score was higher than that of the control group,CRP and IL-2 levels were significantly lower than those of the control group,hemorheology improvement was significantly better than that of the control group,the differences were statistically significant (P<0.05);there was no statistically significant difference in the incidence of adverse reactions between the two groups (P>0.05).Conclusion:The application of Agatroban combined with Eurekline in the treatment of cerebral infarction can effectively promote the functional recovery of patients,improve the neurological defects,reduce the level of inflammatory factors,so as to improve the prognosis of the disease and improve the quality of life of patients,without increasing the incidence of adverse reactions,and is worthy of clinical promotion and use.

关 键 词：脑梗死 阿加曲班 尤瑞克林 

分 类 号：R743.33[医药卫生—神经病学与精神病学]